【摘要】 目的:探讨华法林用于老年持续性房颤患者抗凝治疗的有效性及安全性。方法:入选符合本研究标准的138例老年持续性房颤患者,随机分为两组,华法林组(治疗组)69例,男41例,女28例,以华法林3mg作为起始剂量,按研究设计在不同时点检测国际标准化比值。阿司匹林组(对照组)69例,阿司匹林300mg/d,晚饭后即刻服用,每月随访1次。观察两组不良反应的发生情况。结果:治疗组7~15d(平均10.0±4.8d)国际标准化比值达到1.5~3.0,其比值在1.8~2.5占91.3%。治疗组发生出血2例(2.9%),脑梗死2例(2.9%),上腹不适2例(2.9%)。对照组发生出血2例(2.9%),脑梗死11例(16.2%),上腹不适10例(14.5%)。治疗组脑梗死、上腹不适的发生率低于对照组(P<0.05),两组间出血发生率无统计学差异(P<0.05)。结论:对老年持续性房颤患者应用华法林抗凝治疗能降低中风及上腹部不适的发生率,既有效又安全。更多还原

【Abstract】 Objective To observe the efficacy and safety of wa rf arin in the treatment of atrial fibrillation in the old patients. Methods One hundred and thirty-eight old patients with atrial fibrillation were divided into warfarin group(n=69)and aspirin group(n=69)randomly. In warfarin group patients received warfarin anticoagulation treatment. The patien ts in control group only received aspirin anticoagulation treatment. INR an d side-effect were observed at different time-point respectively. Result s INR reached 1.5～3.0 by antithrombotic therapy with warfarin after 5～7 days, 91.3% of INR reached 1.8～2.5 after 5～7 days. Hemorrhage of warfarin grou p and aspirin group was 2.9% and 2.9% respectively (P<0.05). Stoke of warfar in group and aspirin group was 2.9% and 16.2% respectively (P<0.05). Midsect ion-discomfort of warfarin group and aspirin group was 2.9% and 14.5% respectiv ely (P<0.05). Conclusion Antithrombotic therapy with warfari n in the old patients with atrial fibrillation can significantly reduce the ris k of cardioembolic stroke and the side-effect of midsection-discomfort, and it is effective and safe.更多还原